Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$4.36 and last traded at C$4.27, with a volume of 1001 shares trading hands. The stock had previously closed at C$4.36.
Analyst Ratings Changes
Separately, Alliance Global Partners upgraded shares of Aptose Biosciences to a "strong-buy" rating in a report on Thursday, February 27th.
Get Our Latest Stock Analysis on APS
Aptose Biosciences Stock Performance
The company has a 50-day moving average of C$8.09 and a 200-day moving average of C$11.81. The company has a market cap of C$194.62 million, a PE ratio of -0.90 and a beta of 1.36. The company has a quick ratio of 5.41, a current ratio of 1.05 and a debt-to-equity ratio of -117.37.
About Aptose Biosciences
(
Get Free Report)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Further Reading
Before you consider Aptose Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aptose Biosciences wasn't on the list.
While Aptose Biosciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
